Finance

Lists
IMMX:NASDAQ
Immix Biopharma Inc
6,96 USD
-1,14%
(-0,080) 1D
6,96 USD
0,00% (0,00)
After hours
Closed: 20-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMMX...
Open
7,00 USD
High
7,50 USD
Low
6,90 USD
Mkt. cap
583,33 млн
Avg. vol.
1,19 млн
Volume
1,57 млн
52-wk high
15,10 USD
52-wk low
3,78 USD
EPS
-0,82 USD
Beta
0,29
Shares outstanding
83,81 млн
No. of employees
21
Open
7,00 USD
High
7,50 USD
Low
6,90 USD
Mkt. cap
583,33 млн
Avg. vol.
1,19 млн
Volume
1,57 млн
52-wk high
15,10 USD
52-wk low
3,78 USD
EPS
-0,82 USD
Beta
0,29
Shares outstanding
83,81 млн
No. of employees
21
News stories
From web sources and news partners
About Immix Biopharma Inc
CEO-
Employees21
Founded2012
HeadquartersЛос Анджелес, Калифорния, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 6 analysts giving stock ratings to IMMX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMMX in the last 3 months.
Highest
Current 6,96 USD
30,00 USD (+331,03%)
Average
25,67 USD (+268,82%)
Lowest
21,00 USD (+201,72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
21,00 USD
+201,7%
11/18/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
22,00 USD
+216,1%
11/18/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
27,00 USD
+287,9%
11/16/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
20,00 USD
+187,4%
10/20/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
24,00 USD
+244,8%
10/03/2026
Gil Blum
Needham
Buy
Reiterated
30,00 USD
+331%
09/29/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
30,00 USD
+331%
09/29/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
23,00 USD
+230,5%
03/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5,73 млн
5,98 млн
5,33 млн
5,54 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,17 млн
4,82 млн
7,12 млн
10,40 млн
Operating expense
10,89 млн
10,80 млн
12,46 млн
15,95 млн
Total operating expenses
10,89 млн
10,80 млн
12,46 млн
15,95 млн
Operating income
-10,89 млн
-10,80 млн
-12,46 млн
-15,95 млн
Other non operating income
-
-
-
-
EBT including unusual items
-10,68 млн
-10,09 млн
-11,54 млн
-13,93 млн
EBT excluding unusual items
-10,68 млн
-10,09 млн
-11,54 млн
-13,93 млн
Income tax expense
11,27 миң
-
14,32 миң
-
Effective tax rate
-0,11%
-
-0,12%
-
Other operating expenses
-
-
-
-
Net income
-10,69 млн
-10,09 млн
-11,56 млн
-13,93 млн
Net profit margin
-
-
-
-
Earnings per share
-0,28
-0,18
-0,18
-0,19
Interest and investment income
216,71 миң
717,17 миң
913,66 миң
2,02 млн
Interest expense
-
-
-
-
Net interest expenses
216,71 миң
717,17 миң
913,66 миң
2,02 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,84 млн
-10,71 млн
-12,37 млн
-15,85 млн
Gain or loss from assets sale
-
34,15 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору